Dimension Therapeutics Inc., the Cambridge, Mass.-based company that Regenxbio Inc., of Rockville, Md., moved to acquire on Monday, said it has started dosing participants in the company’s global, multicenter phase I/II study of DTX-301, one of its two lead candidates, for the treatment of patients with ornithine transcarbamylase (OTC) deficiency.